Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

482.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 92
Open 482.30
Bid (Size) 410.00 (1)
Ask (Size) 564.00 (1)
Prev. Close 482.30
Today's Range 482.30 - 482.30
52wk Range 377.85 - 519.88
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.
Via The Motley Fool
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Government
Exposures Political

Performance

YTD
+18.9%
+18.9%
1 Month
-3.5%
-3.5%
3 Month
+17.0%
+17.0%
6 Month
+3.1%
+3.1%
1 Year
+19.2%
+19.2%

More News

Read More
Is Vertex Pharmaceuticals Stock a Buy?
Via The Motley Fool
Exposures Product Safety
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?
Via Benzinga
Topics Stocks World Trade
Exposures Tariff US Equities
Vertex to Announce First Quarter 2025 Financial Results on May 5th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Via Benzinga
2 Stocks to Buy if You're Worried About a Recession
Via The Motley Fool
Topics Economy Government
Exposures Economy Political
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm
Via The Motley Fool
Topics Earnings Economy Government
Exposures Economy Financial Political
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.
Via The Motley Fool
Topics Economy Energy Government
Exposures Economy Fossil Fuels Interest Rates
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
Via Stocktwits
Topics ETFs Government
Exposures COVID-19 Political Product Safety
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
Via Benzinga
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Via Benzinga
Technical Signals Point to a Possible Breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).
Via Chartmill
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Via Benzinga
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession
Via The Motley Fool
Topics Economy Government Stocks
Exposures Economy Political Tariff
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
Via Investor's Business Daily
Exposures Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Via The Motley Fool
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence

Frequently Asked Questions

Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 482.30
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 04/09/25 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 125.12B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 125B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.